Literature DB >> 16298825

Fas, Fas-associated death domain-like interleukin 1beta-converting enzyme-like inhibitory protein, and apoptotic features of elderly acute myeloid leukemia based on response to induction chemotherapy.

Hee-Je Kim1, Byung-Hee Park, Young Choi, Woo-Sung Min, Jong-Wook Lee, Chun-Choo Kim.   

Abstract

A study was performed to examine the clinical outcome of triple-combination induction chemotherapy in 26 elderly Korean acute myeloid leukemia (AML) patients and to investigate apoptotic responses during and after treatment to determine whether the responses can be used as prognostic markers. Patients who had Western blot or polymerase chain reaction analysis findings of higher expression levels of Fas-associated death domain-like interleukin 1beta-converting enzyme-like inhibitory protein (FLIP) on day 7 after chemotherapy were more likely to have complete remission, but there was less or no correlation with Fas or a proapoptosis/apoptosis reaction. Expression of FLIP molecules may be, at least in part, an early prognostic indicator in the treatment of elderly AML patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16298825     DOI: 10.1532/IJH97.A30503

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  31 in total

Review 1.  Fas receptor (CD95)-mediated apoptosis in leukemic cells.

Authors:  Y Komada; M Sakurai
Journal:  Leuk Lymphoma       Date:  1997-03

2.  Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.

Authors:  T Büchner; W Hiddemann; U W Schaefer; H Löffler; G Maschmeyer; W D Ludwig; C Aul; B Lathan; A Heinecke
Journal:  Leukemia       Date:  1992-11       Impact factor: 11.528

3.  Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.

Authors:  N Dastugue; C Payen; M Lafage-Pochitaloff; P Bernard; D Leroux; F Huguet-Rigal; A M Stoppa; G Marit; L Molina; M Michallet
Journal:  Leukemia       Date:  1995-09       Impact factor: 11.528

4.  Hypocellular acute leukemia.

Authors:  R B Howe; C D Bloomfield; R W McKenna
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

5.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

Authors:  B Löwenberg; R Zittoun; H Kerkhofs; U Jehn; J Abels; L Debusscher; C Cauchie; M Peetermans; G Solbu; S Suciu
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

6.  Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.

Authors:  P Gupta; G A Niehans; S C LeRoy; K Gupta; V A Morrison; C Schultz; D J Knapp; R A Kratzke
Journal:  Leukemia       Date:  1999-01       Impact factor: 11.528

7.  Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.

Authors:  C P Leith; I M Chen; K J Kopecky; F R Appelbaum; D R Head; J E Godwin; J K Weick; C L Willman
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

8.  Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response.

Authors:  Jan Braess; Peter Schneiderat; Claudia Schoch; Michael Fiegl; Isolde Lorenz; Wolfgang Hiddemann
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

Review 9.  Acute myeloid leukemia in the older patient.

Authors:  John E Godwin; Scott E Smith
Journal:  Crit Rev Oncol Hematol       Date:  2003-10-15       Impact factor: 6.312

10.  Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases.

Authors:  L Detourmignies; E Wattel; J L Laï; F Bauters; P Fenaux
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.